Clinical Trials Logo
  1. Home
  2. Alpha 1-Antitrypsin Deficiency
  3. NCT00500123

The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study — ACT  

Alpha-1 Antitrypsin Deficiency Clinical Trial

Official title:
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study

Clinical Trial Summary

The Alpha-1 Coded Testing (ACT) Study was established to study genetic testing and outcomes of individuals at risk for alpha-1 antitrypsin deficiency.

Clinical Trial Description

Genetic testing for alpha-1 antitrypsin deficiency is sometimes delayed despite established testing indications. All genetic tests have risks and possible benefits. The ACT study evaluates the population demographics, reasons for testing, and outcomes through a confidential testing program. Co-morbidities of alpha-1 antitrypsin deficiency other than lung and liver disease are being investigated. Concerns about genetic confidentiality are lessened in this study by a coded testing procedure that returns results through the mail to study participants. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00500123
Study type Observational [Patient Registry]
Source University of Florida
Contact Jesse West, RN, CCRC
Phone 352-273-8666
Email jesse.west@medicine.ufl.edu
Status Recruiting
Phase
Start date January 2001
Completion date January 2050
View Details
See also
  Status Clinical Trial Phase
Completed NCT02547532 - Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Completed NCT00005292 - Alpha1-antitrypsin Deficiency Registry N/A
Withdrawn NCT02900183 - Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels Phase 2
Terminated NCT02502201 - Environment Effect on Six-Minute Walk Test Performance N/A
Completed NCT01810458 - Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
Active, not recruiting NCT04262284 - Respreeza® Self-administration and Learning Program (AmAREtTI Study)
Recruiting NCT06186492 - A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1) Phase 1
Recruiting NCT06405633 - A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD Phase 1/Phase 2
Completed NCT01054339 - Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency Phase 2
Completed NCT03815396 - Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency Phase 1
Completed NCT03008915 - Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency Phase 2
Completed NCT01419158 - Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD) N/A
Completed NCT05727800 - A Phase 1, First-in-human Study of VX-668 Phase 1
Active, not recruiting NCT05643495 - A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype Phase 2
Completed NCT02810327 - Alpha-1 Carrier Genomics Study
Terminated NCT02363946 - A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD) Phase 1
Completed NCT03804021 - Long-Term Follow-up Study of ADVM-043
Active, not recruiting NCT02014415 - Alpha-1 Antitrypsin Deficiency Adult Liver Study
Terminated NCT01241942 - Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability N/A